STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
LinkMed’s (STO:LMED) portfolio company AbSorber recently received FDA approval in the U.S. for its patented transplantation test XM-ONE®. Now AbSorber has received further support for its transplantation test from a major clinical trial in which six well-reputed transplantation centers in the U.S. and Sweden participated. The results of the study show that XM-ONE® provides valuable information that refines the diagnostics of matching the right organ with the right patient, thereby increasing the probability of a successful transplantation.
